SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?


To: D.Right who wrote (1263)3/10/1998 11:01:00 AM
From: celeryroot.com  Read Replies (2) | Respond to of 2173
 
This just filed, as I have not been paying to much attention I don't know if this is more or less then previous:

------------------------------
(Name of Issuer)

COMMON STOCK
---------------------------------
(Title of Class of Securities)

032346108
-----------------------
(Cusip Number)

1The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided in
a prior cover page.

The information required in the remainder of this cover page shall
not be deemed to be "filed" for the purpose of Section 18 of the
Securities Exchange Act of 1934 ("Act") or otherwise subject to the
liabilities of that section of the Act, but shall be subject to all
other provisions of the Act (however, see the Notes.)

[Continued on the following page(s)]

Page 1 of 7 Pages

CUSIP No. 032346108 13G Page 2 of 7 Pages
----------------------------------------------------------------
1. Name of reporting persons
S.S. or I.R.S. identification no. of above persons

Wellington Management Company, LLP
04-2683227
----------------------------------------------------------------
2. Check the appropriate box if a member of a group*
(a)[ ]
(b)[ ]
----------------------------------------------------------------
3. SEC use only

----------------------------------------------------------------
4. Citizenship or place of organization
Massachusetts

----------------------------------------------------------------
5. Sole Voting Power
0
Number of -----------------------------
shares 6. Shared Voting Power
beneficially
owned by 1,527,500
each -----------------------------
reporting 7. Sole Dispositive Power
person
with 0
-----------------------------
8. Shared Dispositive Power
3,743,280
---------------------------------------------------------------
9. Aggregate amount beneficially owned by each reporting person

3,743,280
----------------------------------------------------------------
10. Check box if the aggregate amount in row (9) excludes certain shares*
[ ]
----------------------------------------------------------------
11. Percent of class represented by amount in row 9
11.61%
----------------------------------------------------------------
12. Type of reporting person
IA, HC

CUSIP No. 032346108 13G Page 3 of 7 Pages

Item 1(a). Name of Issuer:

AMYLIN PHARMACEUTICALS, INC.

Item 1(b). Address of Issuer's Principal Executive Offices:

9373 Towne Centre Drive
San Diego CA 92121

Item 2(a). Name of Person Filing:

Wellington Management Company, LLP ("WMC")

Item 2(b). Address of Principal Business Office or, if None,
Residence:

75 State Street
Boston, Massachusetts 02109

Item 2(c). Citizenship:

Massachusetts

Item 2(d). Title of Class of Securities:

COMMON STOCK

Item 2(e). CUSIP Number:

032346108

Item 3. If this statement is filed pursuant to Rules 13d-1(b), or
13d-2(b), check whether the person filing is a:

(a) [ ] Broker or Dealer registered under Section 15 of the Act,

(b) [ ] Bank as defined in Section 3(a)(6) of the Act,

(c) [ ] Insurance Company as defined in Section 3(a)(19) of the
Act,

(d) [ ] Investment Company registered under Section 8 of the
Investment Company Act,

(e) [ X ] Investment Adviser registered under Section 203 of the
Investment Advisers Act of 1940,

CUSIP No. 032346108 13G Page 4 of 7 Pages

(f) [ ] Employee Benefit Plan, Pension Fund which is subject to
the provisions of the Employee Retirement Income Security
Act of 1974 or Endowment Fund; see 13d-1(b)(1)(ii)(F),

(g) [ X ] Parent Holding Company, in accordance with Rule 13d-
1(b)(1)(ii)(G); see Item 7,

(h) [ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(H).

Item 4. Ownership:

(a) Amount beneficially owned: WMC, in its capacity as
investment adviser, may be deemed to beneficially own
3,743,280 shares of the Issuer which are held of record by
clients of WMC.

(b) Percent of Class: 11.61%

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct
the vote 0
(ii) Shared power to vote or to direct
the vote 1,527,500
(iii) Sole power to dispose or to direct
the disposition of 0
(iv) Shared power to dispose or to direct
the disposition of 3,743,280

CUSIP No. 032346108 13G Page 5 of 7 Pages

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of
the date hereof the reporting person has ceased to be the
beneficial owner of more than five percent of the class of
securities, check the following [ ].

Item 6. Ownership of More than Five Percent on Behalf of Another
Person.

The securities as to which this Schedule is filed by WMC, in
its capacity as investment adviser, are owned of record by
clients of WMC. Those clients have the right to receive, or
the power to direct the receipt of, dividends from, or the
proceeds from the sale of, such securities. No such client is
known to have such right or power with respect to more than
five percent of this class of securities, except as follows:

None


Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on by the Parent Holding
Company.

See Exhibit A

Item 8. Identification and Classification of Members of the Group.

Not Applicable. This schedule is not being filed pursuant to
Rule 13d-1(b)(1)(ii)(H) or Rule 13d-1(c).

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certification.

"By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were acquired in
the ordinary course of business and were not acquired for the
purpose of and do not have the effect of changing or
influencing the control of the issuer of such securities and
were not acquired in connection with or as a participant in
any transaction having such purpose or effect."

CUSIP No. 032346108 13G Page 6 of 7 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this
statement is true, complete and correct.

Date: March 9, 1998
Signature: --//Brian P. Hillery//--
Name/Title: Brian P. Hillery
Assistant Vice President



To: D.Right who wrote (1263)3/10/1998 11:12:00 AM
From: Rudy Saucillo  Read Replies (2) | Respond to of 2173
 
Agreed. Most of my comments were "old news". I was simply comparing AMLN vs. ERGO and showing that ERGO represents a substantially lower risk and much greater financial potential than AMLN at this point in time - for JNJ and investors.

The AMLN data released last Aug. is very weak considering that AMLN had to search for a subgroup of trial participants that reached the -0.5% change in HbA1c point. This was not an apriori decision. They had to dig for positive results. It's not clear to me that the FDA (or Europe) will give even limited approval based on this minimal response in a patient subpopulation. An effective glucose control drug should, ideally, drive insulin requirements down; not be overwhelmed by it.

Assuming that eventually the FDA does approve pramlintide for use in Type I patients with poor glucose control with stable insulin dosing, it's important to realize that this is a small percent of Type I diabetics. Hence my previous comments that this is no $300-$400 million drug. One more comment...the FDA will not give blanket approval for use in all Type I's if the Phase III data doesn't support it and it's unlikely physicians will use pramlintide off-label if overall efficacy hasn't been established.

I hope the ongoing trials are substantially more positive than the previous ones. But, IMO, there's no reason to believe they will be.

BTW, I have no vested interest in the performance of AMLN stock. I've never been long or short AMLN and have no plans to.